Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of STRO 006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic

NCT07807345 is registered in ClinicalTrials.gov with Sutro Biopharma, Inc. as lead sponsor.

NCT NCT07807345
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07807345 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of STRO 006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic
Lead sponsor
Sutro Biopharma, Inc.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
September 14, 2026
Completion date
December 31, 2028
Enrollment
285 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, colorectal cancer, endometrial cancer, esophageal cancer, gastric cancer, head & neck squamous cell carcinoma, non-small cell lung cancer, urothelial carcinoma (uc)